Brain MetastasesMET-MRINCT07197632
ioMRI in the Surgery of Brain Metastases.
A study testing Surgery with intraoperative MRI in people with Brain Metastases, run by Technical University of Munich at 1 site in Germany.
Trial summary
The study aims to improve the surgical treatment of brain metastases through the use of advanced imaging techniques. The investigators are examining how intraoperative MRI (iMRI) can aid surgeons in precisely locating and removing tumors, with the potential to enhance surgical outcomes and reduce the need for… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain Metastases
- What is being tested?
- Surgery with intraoperative MRI
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 154 participants
- Where
- 1 siteGermany
- Study dates
- 17 Jan 2025to 1 Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients for whom surgical resection of brain metastasis is indicated
Who cannot join
- age < 18
- 3T MRI contraindications
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Department of Neurosurgery, München University Hospital rechts der Isar (MRI)
Munich, 81675
Maria Goldberg, +498941402151, maria.goldberg@tum.de
About this study
Official title: Evaluation of the Efficacy and Safety of Intraoperative MRI in the Surgery of Brain Metastases.
The study aims to improve the surgical treatment of brain metastases through the use of advanced imaging techniques. The investigators are examining how intraoperative MRI (iMRI) can aid surgeons in precisely locating and removing tumors, with the potential to enhance surgical outcomes and reduce the need for additional procedures. While iMRI offers the promise of better tumor visualization during surgery, it is also associated with longer surgical times and may carry the risk of increased complications. This study seeks to carefully evaluate these aspects to determine the overall benefits and challenges of iMRI in brain metastasis surgeries. The ultimate aim is to enhance treatment effectiveness and improve recovery and health outcomes for participants dealing with brain metastases.
- Conditions
- Brain Metastases
- Being tested
- Surgery with intraoperative MRI
- Keywords
- ioMRI, Brain metastases, Neurosurgical resection
- Medical subject headings
- Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgery with intraoperative MRIProcedure or surgery
In this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically
| Study group | Role | What they receive |
|---|---|---|
| Surgery without intraoperative MRI | No intervention | Not described |
| Surgery with intraoperative MRI | Experimental | Not described Receives: Procedure: Surgery with intraoperative MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate for complete resection
The postoperative MRI obtained within 72 hours after surgery will be analyzed to identify the rates of resection.
Measured: immediately after the surgery
Secondary outcomes (1)
Complications
Hemorrhages, Ischemias, epileptic seizures, hydrocephalus, wound infection, Anesthesiological complications, neurological deficits
Measured: Perioperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start17 Jan 2025
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain MetastasesStudies of the same condition, open and under way.
- More trials run by Technical University of MunichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 154 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Technical University of Munich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07197632
- Sponsor's protocol ID
- 2024-452-S-KK Votum 12.12.2024
- Acronym
- MET-MRI
- Status last verified
- May 2026
- First submitted
- 22 Mar 2025
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficacy and Safety of Intraoperative MRI in the Surgery of Brain Metastases.
- ClinicalTrials.gov ID
- NCT07197632
- Acronym / sponsor ID
- MET-MRI / 2024-452-S-KK Votum 12.12.2024
- Conditions
- Brain Metastases
- Keywords
- ioMRI, Brain metastases, Neurosurgical resection
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 154 participants (estimated)
- Lead sponsor
- Technical University of MunichUniversity, hospital or other
- Study start
- 17 Jan 2025 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jan 2030 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to improve the surgical treatment of brain metastases through the use of advanced imaging techniques. The investigators are examining how intraoperative MRI (iMRI) can aid surgeons in precisely locating and removing tumors, with the potential to enhance surgical outcomes and reduce the need for additional procedures. While iMRI offers the promise of better tumor visualization during surgery, it is also associated with longer surgical times and may carry the risk of increased complications. This study seeks to carefully evaluate these aspects to determine the overall benefits and challenges of iMRI in brain metastasis surgeries. The ultimate aim is to enhance treatment effectiveness and improve recovery and health outcomes for participants dealing with brain metastases.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Surgery without intraoperative MRI | No intervention | – |
| Surgery with intraoperative MRI | Experimental | Procedure: Surgery with intraoperative MRI |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients for whom surgical resection of brain metastasis is indicated
Key exclusion criteria (2 listed)
- age < 18
- 3T MRI contraindications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgery with intraoperative MRIIn this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically | Procedure or surgery | Surgery with intraoperative MRI |
Primary outcome
Rate for complete resection
Time frame: immediately after the surgery
The postoperative MRI obtained within 72 hours after surgery will be analyzed to identify the rates of resection.
1 secondary outcome
Complications
Time frame: Perioperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Brain Metastases
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
Epidural Hydroxyethyl Starch for Post-Dural Puncture Headache in Parturients
Parturients, Accidental Puncture of Dura During Anaesthesia
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
RecruitingPhase 2/3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Surgery with intraoperative MRI in people with Brain Metastases, run by Technical University of Munich at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maria Goldberg (+498941402151, maria.goldberg@tum.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate for complete resection (time frame: immediately after the surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.